Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 20
Filtrar
Más filtros

Banco de datos
Tipo del documento
Intervalo de año de publicación
1.
J Lipid Res ; 56(3): 703-712, 2015 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-25561459

RESUMEN

Reverse cholesterol transport (RCT) contributes to the anti-atherogenic effects of HDL. Patients with the orphan disease, familial hypoalphalipoproteinemia (FHA), are characterized by decreased tissue cholesterol removal and an increased atherogenic burden. We performed an open-label uncontrolled proof-of-concept study to evaluate the effect of infusions with a human apoA-I-containing HDL-mimetic particle (CER-001) on RCT and the arterial vessel wall in FHA. Subjects received 20 infusions of CER-001 (8 mg/kg) during 6 months. Efficacy was assessed by measuring (apo)lipoproteins, plasma-mediated cellular cholesterol efflux, fecal sterol excretion (FSE), and carotid artery wall dimension by MRI and artery wall inflammation by (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography scans. We included seven FHA patients: HDL-cholesterol (HDL-c), 13.8 [1.8-29.1] mg/dl; apoA-I, 28.7 [7.9-59.1] mg/dl. Following nine infusions in 1 month, apoA-I and HDL-c increased directly after infusion by 27.0 and 16.1 mg/dl (P = 0.018). CER-001 induced a 44% relative increase (P = 0.018) in in vitro cellular cholesterol efflux with a trend toward increased FSE (P = 0.068). After nine infusions of CER-001, carotid mean vessel wall area decreased compared with baseline from 25.0 to 22.8 mm(2) (P = 0.043) and target-to-background ratio from 2.04 to 1.81 (P = 0.046). In FHA-subjects, CER-001 stimulates cholesterol mobilization and reduces artery wall dimension and inflammation, supporting further evaluation of CER-001 in FHA patients.


Asunto(s)
Apolipoproteína A-I/administración & dosificación , Arterias Carótidas , HDL-Colesterol/sangre , Hipoalfalipoproteinemias , Angiografía por Resonancia Magnética , Fosfolípidos/administración & dosificación , Tomografía de Emisión de Positrones , Proteínas Recombinantes/administración & dosificación , Adulto , Arterias Carótidas/diagnóstico por imagen , Arterias Carótidas/metabolismo , Femenino , Humanos , Hipoalfalipoproteinemias/sangre , Hipoalfalipoproteinemias/diagnóstico por imagen , Hipoalfalipoproteinemias/tratamiento farmacológico , Masculino , Persona de Mediana Edad , Radiografía
2.
Am Heart J ; 169(5): 736-742.e1, 2015 May.
Artículo en Inglés | MEDLINE | ID: mdl-25965722

RESUMEN

BACKGROUND: Patients with homozygous familial hypercholesterolemia (HoFH) are at extremely elevated risk for early cardiovascular disease because of exposure to elevated low-density lipoprotein cholesterol (LDL-C) plasma levels from birth. Lowering LDL-C by statin therapy is the cornerstone for cardiovascular disease prevention, but the residual risk in HoFH remains high, emphasizing the need for additional therapies. In the present study, we evaluated the effect of serial infusions with CER-001, a recombinant human apolipoprotein A-I (apoA-I)-containing high-density lipoprotein-mimetic particle, on carotid artery wall dimensions in patients with HoFH. METHODS AND RESULTS: Twenty-three patients (mean age 39.4 ± 13.5 years, mean LDL-C 214.2 ± 81.5 mg/dL) with genetically confirmed homozygosity or compound heterozygosity for LDLR, APOB, PCSK9, or LDLRAP1 mutations received 12 biweekly infusions with CER-001 (8 mg/kg). Before and 1 hour after the first infusion, lipid values were measured. Magnetic resonance imaging (3-T magnetic resonance imaging) scans of the carotid arteries were acquired at baseline and after 24 weeks to assess changes in artery wall dimensions. After CER-001 infusion, apoA-I increased from 114.8 ± 20.7 mg/dL to 129.3 ± 23.0 mg/dL. After 24 weeks, mean vessel wall area (primary end point) decreased from 17.23 to 16.75 mm(2) (P = .008). A trend toward reduction of mean vessel wall thickness was observed (0.75 mm at baseline and 0.74 mm at follow-up, P = .0835). CONCLUSIONS: In HoFH, 12 biweekly infusions with an apoA-I-containing high-density lipoprotein-mimetic particle resulted in a significant reduction in carotid mean vessel wall area, implying that CER-001 may reverse atherogenic changes in the arterial wall on top of maximal low-density lipoprotein-lowering therapy. This finding supports further clinical evaluation of apoA-I-containing particles in patients with HoFH.


Asunto(s)
Apolipoproteína A-I/farmacología , Grosor Intima-Media Carotídeo , LDL-Colesterol/sangre , Enfermedad de la Arteria Coronaria/patología , Hiperlipoproteinemia Tipo II/patología , Fosfolípidos/farmacología , Proteínas Recombinantes/farmacología , Adulto , Apolipoproteína A-I/uso terapéutico , Enfermedad de la Arteria Coronaria/tratamiento farmacológico , Femenino , Humanos , Hiperlipoproteinemia Tipo II/tratamiento farmacológico , Hiperlipoproteinemia Tipo II/genética , Lípidos/sangre , Masculino , Persona de Mediana Edad , Fosfolípidos/uso terapéutico , Enfermedades Raras , Proteínas Recombinantes/uso terapéutico
3.
Eur Heart J ; 35(46): 3277-86, 2014 Dec 07.
Artículo en Inglés | MEDLINE | ID: mdl-24780501

RESUMEN

AIM: High-density lipoproteins (HDLs) have several potentially protective vascular effects. Most clinical studies of therapies targeting HDL have failed to show benefits vs. placebo. OBJECTIVE: To investigate the effects of an HDL-mimetic agent on atherosclerosis by intravascular ultrasonography (IVUS) and quantitative coronary angiography (QCA). DESIGN AND SETTING: A prospective, double-blinded, randomized trial was conducted at 51 centres in the USA, the Netherlands, Canada, and France. Intravascular ultrasonography and QCA were performed to assess coronary atherosclerosis at baseline and 3 (2-5) weeks after the last study infusion. PATIENTS: Five hundred and seven patients were randomized; 417 and 461 had paired IVUS and QCA measurements, respectively. INTERVENTION: Patients were randomized to receive 6 weekly infusions of placebo, 3 mg/kg, 6 mg/kg, or 12 mg/kg CER-001. MAIN OUTCOME MEASURES: The primary efficacy parameter was the nominal change in the total atheroma volume. Nominal changes in per cent atheroma volume on IVUS and coronary scores on QCA were also pre-specified endpoints. RESULTS: The nominal change in the total atheroma volume (adjusted means) was -2.71, -3.13, -1.50, and -3.05 mm(3) with placebo, CER-001 3 mg/kg, 6 mg/kg, and 12 mg/kg, respectively (primary analysis of 12 mg/kg vs. placebo: P = 0.81). There was also no difference among groups for the nominal change in per cent atheroma volume (0.02, -0.02, 0.01, and 0.19%; nominal P = 0.53 for 12 mg/kg vs. placebo). Change in the coronary artery score was -0.022, -0.036, -0.022, and -0.015 mm (nominal P = 0.25, 0.99, 0.55), and change in the cumulative coronary stenosis score was -0.51, 2.65, 0.71, and -0.77% (compared with placebo, nominal P = 0.85 for 12 mg/kg and nominal P = 0.01 for 3 mg/kg). The number of patients with major cardiovascular events was 10 (8.3%), 16 (13.3%), 17 (13.7%), and 12 (9.8%) in the four groups. CONCLUSION: CER-001 infusions did not reduce coronary atherosclerosis on IVUS and QCA when compared with placebo. Whether CER-001 administered in other regimens or to other populations could favourably affect atherosclerosis must await further study. Name of the trial registry: Clinicaltrials.gov; Registry's URL: http://clinicaltrials.gov/ct2/show/NCT01201837?term=cer-001&rank=2; TRIAL REGISTRATION NUMBER: NCT01201837.


Asunto(s)
Síndrome Coronario Agudo/tratamiento farmacológico , Apolipoproteína A-I/administración & dosificación , Fármacos Cardiovasculares/administración & dosificación , Enfermedad de la Arteria Coronaria/tratamiento farmacológico , Fosfolípidos/administración & dosificación , Proteínas Recombinantes/administración & dosificación , Síndrome Coronario Agudo/diagnóstico por imagen , Adulto , Anciano , Anciano de 80 o más Años , Apolipoproteína A-I/efectos adversos , Fármacos Cardiovasculares/efectos adversos , Angiografía Coronaria , Enfermedad de la Arteria Coronaria/diagnóstico por imagen , Femenino , Humanos , Infusiones Intravenosas , Masculino , Persona de Mediana Edad , Fosfolípidos/efectos adversos , Estudios Prospectivos , Proteínas Recombinantes/efectos adversos , Resultado del Tratamiento , Ultrasonografía
4.
Metabolism ; 116: 154464, 2021 03.
Artículo en Inglés | MEDLINE | ID: mdl-33309714

RESUMEN

OBJECTIVE: CER-001 is an HDL mimetic that has been tested in different pathological conditions, but never with LCAT deficiency. This study was designed to investigate whether the absence of LCAT affects the catabolic fate of CER-001, and to evaluate the effects of CER-001 on kidney disease associated with LCAT deficiency. METHODS: Lcat-/- and wild-type mice received CER-001 (2.5, 5, 10 mg/kg) intravenously for 2 weeks. The plasma lipid/ lipoprotein profile and HDL subclasses were analyzed. In a second set of experiments, Lcat-/- mice were injected with LpX to induce renal disease and treated with CER-001 and then the plasma lipid profile, lipid accumulation in the kidney, albuminuria and glomerular podocyte markers were evaluated. RESULTS: In Lcat-/- mice a decrease in total cholesterol and triglycerides, and an increase in HDL-c was observed after CER-001 treatment. While in wild-type mice CER-001 entered the classical HDL remodeling pathway, in the absence of LCAT it disappeared from the plasma shortly after injection and ended up in the kidney. In a mouse model of renal disease in LCAT deficiency, treatment with CER-001 at 10 mg/kg for one month had beneficial effects not only on the lipid profile, but also on renal disease, by limiting albuminuria and podocyte dysfunction. CONCLUSIONS: Treatment with CER-001 ameliorates the dyslipidemia typically associated with LCAT deficiency and more importantly limits renal damage in a mouse model of renal disease in LCAT deficiency. The present results provide a rationale for using CER-001 in FLD patients.


Asunto(s)
Apolipoproteína A-I/uso terapéutico , Enfermedades Renales/tratamiento farmacológico , Deficiencia de la Lecitina Colesterol Aciltransferasa/tratamiento farmacológico , Metabolismo de los Lípidos/efectos de los fármacos , Lípidos/sangre , Fosfolípidos/uso terapéutico , Proteínas Recombinantes/uso terapéutico , Animales , Apolipoproteína A-I/farmacología , Células Cultivadas , Modelos Animales de Enfermedad , Enfermedades Renales/genética , Enfermedades Renales/patología , Deficiencia de la Lecitina Colesterol Aciltransferasa/genética , Deficiencia de la Lecitina Colesterol Aciltransferasa/metabolismo , Deficiencia de la Lecitina Colesterol Aciltransferasa/patología , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Fosfatidilcolina-Esterol O-Aciltransferasa/genética , Fosfolípidos/farmacología , Podocitos/efectos de los fármacos , Podocitos/patología , Podocitos/fisiología , Proteínas Recombinantes/farmacología
5.
Atherosclerosis ; 311: 13-19, 2020 10.
Artículo en Inglés | MEDLINE | ID: mdl-32919280

RESUMEN

BACKGROUND AND AIMS: Infusion of high-density lipoprotein (HDL) mimetics failed to induce regression of atherosclerosis in recent randomized clinical trials. However, patients in these previous trials had normal levels of HDL-cholesterol, which potentially limited efficacy. Patients with very low levels of HDL-cholesterol and impaired cholesterol efflux capacity can be expected to derive the most potential benefit from infusion of HDL mimetics. This randomized clinical trial evaluated the efficacy of infusions of the HDL mimetic CER-001 in patients with genetically determined very low levels of HDL cholesterol. METHODS: In this multicenter, randomized clinical trial, we recruited patients with familial hypoalphalipoproteinemia (due to ABCA1 and/or APOA1 loss-of-function variants). Participants were randomized to intravenous infusions of 8 mg/kg CER-001 or placebo (2:1 ratio), comprising 9 weekly infusions followed by infusions every two weeks. Patients underwent repeated 3T-MRI to assess mean vessel wall area and 18F-FDG PET/CT to quantify arterial wall inflammation. RESULTS: A total of 30 patients with a mean age of 52.7 ± 7.4 years and HDL-cholesterol of 0.35 ± 0.25 mmol/L were recruited. After 24 weeks, the absolute change in mean vessel wall area was not significantly different in the CER-001 group compared with placebo (n = 27; treatment difference: 0.77 mm2, p = 0.21). Furthermore, there was no significant difference in carotid arterial wall inflammation (n = 24, treatment difference: 0.10 target-to-background ratio of the most diseased segment, p = 0.33) after 24 weeks. CONCLUSION: In patients with genetically determined very low HDL-cholesterol, 24 weeks of treatment with HDL mimetic CER-001 did not reduce carotid vessel wall dimensions or arterial wall inflammation, compared with placebo.


Asunto(s)
Enfermedades de las Arterias Carótidas , Lipoproteínas HDL , Apolipoproteína A-I , Enfermedades de las Arterias Carótidas/diagnóstico por imagen , Enfermedades de las Arterias Carótidas/tratamiento farmacológico , HDL-Colesterol , Humanos , Persona de Mediana Edad , Fosfolípidos , Tomografía Computarizada por Tomografía de Emisión de Positrones , Proteínas Recombinantes
6.
Ther Deliv ; 9(4): 257-268, 2018 03 01.
Artículo en Inglés | MEDLINE | ID: mdl-29495929

RESUMEN

The physiological role(s) of mammalian plasma lipoproteins is to transport hydrophobic molecules (primarily cholesterol and triacylglycerols) to their respective destinations. Lipoproteins have also been studied as drug-delivery agents due to their advantageous payload capacity, long residence time in the circulation and biocompatibility. The purpose of this review is to briefly discuss current findings with the focus on each type of formulation's potential for clinical applications. Regarding utilizing lipoprotein type formulation for cancer therapeutics, their potential for tumor-selective delivery is also discussed.


Asunto(s)
Composición de Medicamentos/métodos , Sistemas de Liberación de Medicamentos/métodos , Lipoproteínas/química , Nanopartículas/química , Nanomedicina Teranóstica/métodos , Animales , Antineoplásicos/administración & dosificación , Apolipoproteína A-I/administración & dosificación , Aterosclerosis/tratamiento farmacológico , Materiales Biomiméticos/química , Ensayos Clínicos como Asunto , Composición de Medicamentos/tendencias , Sistemas de Liberación de Medicamentos/tendencias , Humanos , Neoplasias/tratamiento farmacológico , Fosfolípidos/administración & dosificación , Proteínas Recombinantes/administración & dosificación , Nanomedicina Teranóstica/tendencias
7.
JAMA Cardiol ; 3(9): 815-822, 2018 09 01.
Artículo en Inglés | MEDLINE | ID: mdl-30046828

RESUMEN

Importance: CER-001 is a negatively charged, engineered pre-ß high-density lipoprotein (HDL) mimetic containing apolipoprotein A-I and sphingomyelin. Preliminary studies demonstrated favorable effects of CER-001 on cholesterol efflux and vascular inflammation. A post hoc reanalysis of a previously completed study of intravenous infusion of CER-001, 3 mg/k, showed that the intravenous infusion in patients with a high coronary plaque burden promoted regression as assessed by intravascular ultrasonography. Objective: To determine the effect of infusing CER-001 on coronary atherosclerosis progression in statin-treated patients. Design, Setting, and Participants: A double-blind, randomized, multicenter trial evaluating the effect of 10 weekly intravenous infusions of CER-001, 3 mg/kg, (n = 135) or placebo (n = 137) in patients with an acute coronary syndrome (ACS) and baseline percent atheroma volume (PAV) greater than 30% in the proximal segment of an epicardial artery by intravascular ultrasonography. The study included 34 academic and community hospitals in Australia, Hungary, the Netherlands, and the United States in patients with ACS presenting for coronary angiography. Patients were enrolled from August 15, 2015, to November 19, 2016. Interventions: Participants were randomized to receive weekly CER-001, 3 mg/kg, or placebo for 10 weeks in addition to statins. Main Outcomes and Measures: The primary efficacy measure was the nominal change in PAV from baseline to day 78 measured by serial intravascular ultrasonography imaging. The secondary efficacy measures were nominal change in normalized total atheroma volume and percentage of patients demonstrating plaque regression. Safety and tolerability were also evaluated. Results: Among 293 patients (mean [SD] age, 59.8 [9.4] years; 217 men [79.8%] and 261 white race/ethnicity [96.0%]), 86 (29%) had statin prior use prior to the index ACS and 272 (92.8%) had evaluable imaging at follow-up. The placebo and CER-001 groups had similar posttreatment median levels of low-density lipoprotein cholesterol (74 mg/dL vs 79 mg/dL; P = .15) and high-density lipoprotein cholesterol (43 mg/dL vs 44 mg/dL; P = .66). The primary efficacy measure, PAV, decreased 0.41% with placebo (P = .005 compared with baseline), but not with CER-001 (-0.09%; P = .67 compared with baseline; between group differences, 0.32%; P = .15). Similar percentages of patients in the placebo and CER-001 groups demonstrated regression of PAV (57.7% vs 53.3%; P = .49). Infusions were well tolerated, with no differences in clinical and laboratory adverse events observed between treatment groups. Conclusions and Relevance: Infusion of CER-001 did not promote regression of coronary atherosclerosis in statin-treated patients with ACS and high plaque burden. Trial Registration: ClinicalTrials.gov Identifier: NCT2484378.


Asunto(s)
Síndrome Coronario Agudo/diagnóstico por imagen , Síndrome Coronario Agudo/tratamiento farmacológico , Apolipoproteína A-I/administración & dosificación , Enfermedad de la Arteria Coronaria/diagnóstico por imagen , Enfermedad de la Arteria Coronaria/tratamiento farmacológico , Inhibidores de Hidroximetilglutaril-CoA Reductasas/administración & dosificación , Fosfolípidos/administración & dosificación , Proteínas Recombinantes/administración & dosificación , Anciano , Apolipoproteína A-I/uso terapéutico , Australia , Progresión de la Enfermedad , Método Doble Ciego , Esquema de Medicación , Femenino , Humanos , Hungría , Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéutico , Bombas de Infusión , Masculino , Persona de Mediana Edad , Países Bajos , Fosfolípidos/uso terapéutico , Proteínas Recombinantes/uso terapéutico , Resultado del Tratamiento , Ultrasonografía Intervencional , Estados Unidos
8.
Clin Drug Investig ; 37(5): 483-491, 2017 May.
Artículo en Inglés | MEDLINE | ID: mdl-28213743

RESUMEN

BACKGROUND: CER-001 comprises recombinant human apolipoprotein A-I complexed with phospholipids that mimics natural, nascent, pre-ß high-density lipoprotein (HDL). We present animal model data showing dose-dependent increases in cholesterol efflux with CER-001 and its subsequent elimination by reverse lipid transport, together with inhibition of atherosclerotic plaque progression. We report the first phase I study results with CER-001 in humans, starting at 0.25 mg/kg, which is 1/80th of the safe dose (20 mg/kg) established in 4-week multiple-dose animal studies dosed every second day. METHODS: Healthy volunteers, 18-55 years old with a low-density lipoprotein-cholesterol:HDL-cholesterol ratio greater than 3.0, received single intravenous escalating doses of CER-001 (0.25-45.0 mg/kg) and placebo in a double-blind randomised cross-over fashion. Subjects were followed up for 3 weeks post-dose. Assessments included adverse event monitoring, blood sampling, and clinical laboratory measurements. RESULTS: Thirty-two subjects were enrolled. All CER-001 doses (0.25-45 mg/kg) were safe and well tolerated, with an adverse event profile similar to placebo. Effects on clinical chemistry, haematology and coagulation parameters were comparable to placebo. No adverse effects of CER-001 on electrocardiograms were observed. No antibodies to apolipoprotein A-I were detected following single-dose administration of CER-001. Plasma apolipoprotein A-I levels increased in a dose-related manner and returned to baseline by 24 h post-dose for doses up to 10 mg/kg but remained in circulation for >72 h post-dose for doses >10 mg/kg. CER-001 caused elevations in plasma cholesterol and total and unesterified cholesterol in the HDL fraction. Mobilisation of unesterified cholesterol in the HDL fraction was seen with CER-001 at doses as low as 2 mg/kg. CONCLUSION: CER-001 is well tolerated when administered to humans as single doses up to 45 mg/kg and mobilises and eliminates cholesterol via reverse lipid transport.


Asunto(s)
Apolipoproteína A-I/sangre , Apolipoproteína A-I/uso terapéutico , Colesterol/sangre , Fosfolípidos/uso terapéutico , Proteínas Recombinantes/uso terapéutico , Adulto , Animales , Apolipoproteína A-I/farmacología , HDL-Colesterol/antagonistas & inhibidores , HDL-Colesterol/sangre , LDL-Colesterol/antagonistas & inhibidores , LDL-Colesterol/sangre , Estudios Cruzados , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Evaluación Preclínica de Medicamentos/métodos , Femenino , Humanos , Masculino , Ratones , Ratones Noqueados , Persona de Mediana Edad , Fosfolípidos/farmacología , Conejos , Proteínas Recombinantes/farmacología
9.
Cardiovasc Diagn Ther ; 7(3): 252-263, 2017 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-28567351

RESUMEN

BACKGROUND: CER-001 is an engineered pre-beta high-density lipoprotein (HDL) mimetic, which rapidly mobilizes cholesterol. Infusion of CER-001 3 mg/kg exhibited a potentially favorable effect on plaque burden in the CHI-SQUARE (Can HDL Infusions Significantly Quicken Atherosclerosis Regression) study. Since baseline atheroma burden has been shown as a determinant for the efficacy of HDL infusions, the degree of baseline atheroma burden might influence the effect of CER-001. METHODS: CHI-SQUARE compared the effect of 6 weekly infusions of CER-001 (3, 6 and 12 mg/kg) vs. placebo on coronary atherosclerosis in 369 patients with acute coronary syndrome (ACS) using serial intravascular ultrasound (IVUS). Baseline percent atheroma volume (B-PAV) cutoff associated with atheroma regression following CER-001 infusions was determined by receiver-operating characteristics curve analysis. 369 subjects were stratified according to the cutoff. The effect of CER-001 at different doses was compared to placebo in each group. RESULTS: A B-PAV ≥30% was the optimal cutoff associated with PAV regression following CER-001 infusions. CER-001 induced PAV regression in patients with B-PAV ≥30% but not in those with B-PAV <30% (-0.45%±2.65% vs. +0.34%±1.69%, P=0.01). Compared to placebo, the greatest PAV regression was observed with CER-001 3mg/kg in patients with B-PAV ≥30% (-0.96%±0.34% vs. -0.25%±0.31%, P=0.01), whereas there were no differences between placebo (+0.09%±0.36%) versus CER-001 in patients with B-PAV <30% (3 mg/kg; +0.41%±0.32%, P=0.39; 6 mg/kg; +0.27%±0.36%, P=0.76; 12 mg/kg; +0.32%±0.37%, P=0.97). CONCLUSIONS: Infusions of CER-001 3 mg/kg induced the greatest atheroma regression in ACS patients with higher B-PAV. These findings identify ACS patients with more extensive disease as most likely to benefit from HDL mimetic therapy.

10.
Cardiovasc Diagn Ther ; 7(1): 45-51, 2017 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-28164012

RESUMEN

BACKGROUND: High-density lipoprotein (HDL) is believed to have atheroprotective properties, but an effective HDL-based therapy remains elusive. Early studies have suggested that infusion of reconstituted HDL promotes reverse cholesterol transport and vascular reactivity. The CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial (CARAT) is investigating the impact of infusing an engineered pre-beta HDL mimetic containing sphingomyelin (SM) and dipalmitoyl phosphatidlyglycerol (CER-001) on coronary atheroma volume in patients with a recent acute coronary syndrome (ACS). METHODS: The CARAT is a phase 2, multicenter trial in which 292 patients with an ACS undergoing intracoronary ultrasonography and showing percent atheroma volume (PAV) greater than 30% are randomly assigned to treatment with ten infusions of CER-001 3 mg/kg or matching placebo, administered at weekly intervals. Intracoronary ultrasonography is repeated at the end of the treatment period. RESULTS: The primary endpoint is the nominal change in PAV. Safety and tolerability will also be evaluated. CONCLUSIONS: CARAT will establish whether serial 3 mg/kg infusions of an engineered pre-beta HDL mimetic containing SM and dipalmitoyl phosphatidlyglycerol (CER-001) will regress atherosclerotic plaque in patients with a recent ACS.

11.
J Med Chem ; 49(1): 334-48, 2006 Jan 12.
Artículo en Inglés | MEDLINE | ID: mdl-16392818

RESUMEN

A series of long (11-15) hydrocarbon chain diols and diacids with various central functional groups and terminal gem-dimethyl or -methyl/aryl substituents was synthesized and evaluated in both in vivo and in vitro assays for its potential to favorably alter lipid disorders including metabolic syndrome. Compounds were assessed for their effects on the de novo incorporation of radiolabeled acetate into lipids in primary cultures of rat hepatocytes, as well as for their effects on lipid and glycemic variables in obese female Zucker fatty rats, Crl:(ZUC)-faBR. The most active compounds were hydroxyl-substituted symmetrical diacids and diols with a 13-atom chain and terminal gem-dimethyl substituents. Furthermore, biological activity was enhanced by central substitution with O, C=O, S, S=O compared to the methylene analogues and was diminished for compounds with central functional groups such as carbamate, ester, urea, acetylmethylene, and hydroxymethylene.


Asunto(s)
Alcoholes/uso terapéutico , Diabetes Mellitus Experimental/tratamiento farmacológico , Ácidos Dicarboxílicos/uso terapéutico , Hidrocarburos/uso terapéutico , Hiperlipidemias/tratamiento farmacológico , Hipolipemiantes/uso terapéutico , Administración Oral , Alcoholes/administración & dosificación , Alcoholes/síntesis química , Animales , Diabetes Mellitus Experimental/metabolismo , Ácidos Dicarboxílicos/administración & dosificación , Ácidos Dicarboxílicos/síntesis química , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Tolerancia a Medicamentos , Femenino , Hepatocitos/efectos de los fármacos , Hidrocarburos/administración & dosificación , Hidrocarburos/síntesis química , Hiperlipidemias/metabolismo , Hipolipemiantes/administración & dosificación , Hipolipemiantes/síntesis química , Técnicas In Vitro , Lípidos/antagonistas & inhibidores , Lípidos/biosíntesis , Estructura Molecular , Ratas , Ratas Zucker , Relación Estructura-Actividad , Factores de Tiempo
12.
Int J Cardiol ; 215: 364-71, 2016 Jul 15.
Artículo en Inglés | MEDLINE | ID: mdl-27128563

RESUMEN

OBJECTIVES: High-density lipoprotein (HDL) infusions induce rapid improvement of experimental atherosclerosis in rabbits but their effect on ventricular function remains unknown. We aimed to evaluate the effects of the HDL mimetic peptide CER-522 on left ventricular diastolic dysfunction (LVDD). METHODS: Rabbits were fed with a cholesterol- and vitamin D2-enriched diet until mild aortic valve stenosis and hypercholesterolemia-induced LV hypertrophy and LVDD developed. Animals then received saline or 10 or 30mg/kg CER-522 infusions 6 times over 2weeks. We performed serial echocardiograms and LV histology to evaluate the effects of CER-522 therapy on LVDD. RESULTS: LVDD was reduced by CER-522 as shown by multiple parameters including early filling mitral deceleration time, deceleration rate, Em/Am ratio, E/Em ratio, pulmonary venous velocities, and LVDD score. These findings were associated with reduced macrophages (RAM-11 positive cells) in the pericoronary area and LV, and decreased levels of apoptotic cardiomyocytes in CER-522-treated rabbits. CER-522 treatment also resulted in decreased atheromatous plaques and internal elastic lamina area in coronary arteries. CONCLUSIONS: CER-522 improves LVDD in rabbits, with reductions of LV macrophage accumulation, cardiomyocyte apoptosis, coronary atherosclerosis and remodelling.


Asunto(s)
Estenosis de la Válvula Aórtica/fisiopatología , Colesterol/administración & dosificación , Hipercolesterolemia/fisiopatología , Hipertrofia Ventricular Izquierda/tratamiento farmacológico , Peptidomiméticos/administración & dosificación , Disfunción Ventricular Izquierda/tratamiento farmacológico , Animales , Estenosis de la Válvula Aórtica/inducido químicamente , Apoptosis/efectos de los fármacos , Células Cultivadas , Colesterol/efectos adversos , Modelos Animales de Enfermedad , Humanos , Hipercolesterolemia/inducido químicamente , Hipertrofia Ventricular Izquierda/fisiopatología , Lipoproteínas HDL/química , Macrófagos/citología , Macrófagos/efectos de los fármacos , Miocitos Cardíacos/citología , Miocitos Cardíacos/efectos de los fármacos , Peptidomiméticos/farmacología , Conejos , Disfunción Ventricular Izquierda/fisiopatología
13.
Atherosclerosis ; 251: 381-388, 2016 08.
Artículo en Inglés | MEDLINE | ID: mdl-27263077

RESUMEN

BACKGROUND AND AIMS: Infusion of high-density lipoprotein (HDL) mimetics aimed at reducing atherosclerotic burden has led to equivocal results, which may relate in part to the inability of HDL mimetics to adequately reach atherosclerotic lesions in humans. This study evaluated delivery of recombinant human apolipoprotein A-I (apoA-I) containing HDL mimetic CER-001 in carotid plaques in patients. METHODS: CER-001 was radiolabeled with the long-lived positron emitter zirconium-89 ((89)Zr) to enable positron emission tomography with computed tomography (PET/CT) imaging. Eight patients with atherosclerotic carotid artery disease (>50% stenosis) received a single infusion of unlabeled CER-001 (3 mg/kg), co-administered with 10 mg of (89)Zr-labeled CER-001 (18 MBq). Serial PET/CT imaging and contrast enhanced-magnetic resonance imaging (CE-MRI) were performed to evaluate targeted delivery of CER-001. RESULTS: One hour after infusion, mean plasma apoA-I levels increased by 9.9 mg/dL (p = 0.026), with a concomitant relative increase in the plasma cholesterol efflux capacity of 13.8% (p < 0.001). Using serial PET/CT imaging, we showed that arterial uptake of CER-001 expressed as target-to-background ratio (TBRmax) increased significantly 24 h after infusion, and remained increased up to 48 h (TBRmax t = 10 min: 0.98; t = 24 h: 1.14 (p = 0.001); t = 48 h: 1.12 (p = 0.007)). TBRmax was higher in plaque compared with non-plaque segments (1.18 vs. 1.05; p < 0.001). Plaque TBRmax correlated with local plaque contrast enhancement (r = 0.56; p = 0.019) as assessed by CE-MRI. CONCLUSIONS: Infusion of HDL mimetic CER-001 increases plasma apoA-I concentration and plasma cholesterol efflux capacity. Our data support the concept that CER-001 targets plaque regions in patients, which correlates with plaque contrast enhancement. These clinical findings may also guide future nanomedicine development using HDL particles for drug delivery in atherosclerosis. CLINICAL TRIAL REGISTRATION: Netherlands Trial Registry - NTR5178. http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=5178.


Asunto(s)
Apolipoproteína A-I/química , Fosfolípidos/química , Placa Aterosclerótica/sangre , Placa Aterosclerótica/tratamiento farmacológico , Proteínas Recombinantes/química , Anciano , Medios de Contraste/química , Portadores de Fármacos , Femenino , Humanos , Lipoproteínas/química , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Nanomedicina , Placa Aterosclerótica/metabolismo , Tomografía de Emisión de Positrones , Tomografía Computarizada por Rayos X , Circonio/química
14.
PLoS One ; 10(9): e0137584, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26335690

RESUMEN

OBJECTIVE: CER-001 is a novel engineered HDL-mimetic comprised of recombinant human apoA-I and charged phospholipids that was designed to mimic the beneficial properties of nascent pre-ß HDL. In this study, we have evaluated the dose-dependent regulation of ABCA1 expression in vitro and in vivo in the presence of CER-001 and native HDL (HDL3). METHODS AND RESULTS: CER-001 induced cholesterol efflux from J774 macrophages in a dose-dependent manner similar to natural HDL. A strong down-regulation of the ATP-binding cassette A1 (ABCA1) transporter mRNA (- 50%) as well as the ABCA1 membrane protein expression (- 50%) was observed at higher doses of CER-001 and HDL3 compared to non-lipidated apoA-I. In vivo, in an apoE-/- mouse "flow cessation model," in which the left carotid artery was ligatured to induce local inflammation, the inhibition of atherosclerotic plaque burden progression in response to a dose-range of every-other-day CER-001 or HDL in the presence of a high-fat diet for two weeks was assessed. We observed a U-shaped dose-response curve: inhibition of the plaque total cholesterol content increased with increasing doses of CER-001 or HDL3 up to a maximum inhibition (- 51%) at 5 mg/kg; however, as the dose was increased above this threshold, a progressively less pronounced inhibition of progression was observed, reaching a complete absence of inhibition of progression at doses of 20 mg/kg and over. ABCA1 protein expression in the same atherosclerotic plaque was decreased by-45% and-68% at 50 mg/kg for CER-001 and HDL respectively. Conversely, a-12% and 0% decrease in ABCA1 protein expression was observed at the 5 mg/kg dose for CER-001 and HDL respectively. CONCLUSIONS: These data demonstrate that high doses of HDL and CER-001 are less effective at slowing progression of atherosclerotic plaque in apoE-/- mice compared to lower doses, following a U-shaped dose-response curve. A potential mechanism for this phenomenon is supported by the observation that high doses of HDL and CER-001 induce a rapid and strong down-regulation of ABCA1 both in vitro and in vivo. In conclusion, maximally efficient HDL- or CER-001-mediated cholesterol removal from atherosclerotic plaque is achieved by maximizing macrophage-mediated efflux from the plaque while minimizing dose-dependent down-regulation of ABCA1 expression. These observations may help define the optimal dose of HDL mimetics for testing in clinical trials of atherosclerotic burden regression.


Asunto(s)
Transportador 1 de Casete de Unión a ATP/metabolismo , Apolipoproteína A-I/farmacología , Regulación hacia Abajo/efectos de los fármacos , Lipoproteínas HDL/farmacología , Fosfolípidos/farmacología , Placa Aterosclerótica/prevención & control , Proteínas Recombinantes/farmacología , Transportador 1 de Casete de Unión a ATP/genética , Animales , Apolipoproteínas E/genética , Relación Dosis-Respuesta a Droga , Ratones , Placa Aterosclerótica/genética , Placa Aterosclerótica/metabolismo
15.
J Med Chem ; 47(21): 5183-97, 2004 Oct 07.
Artículo en Inglés | MEDLINE | ID: mdl-15456261

RESUMEN

Long hydrocarbon chain ethers with bis-terminal hydroxyl or carboxyl groups have been synthesized and evaluated for their potential to favorably alter lipid disorders including metabolic syndrome. Compounds were assessed for their effects on the de novo incorporation of radiolabeled acetate into lipids in primary cultures of rat hepatocytes as well as for their effects on lipid and glycemic variables in female obese Zucker fatty rats following 1 and 2 weeks of daily oral administration. The most active compounds were found to be symmetrical with four to five methylene groups separating the central ether functionality and the gem dimethyl or methyl/aryl substituents. Biological activity was found to be greatest for tetramethyl-substituted ether diols (e.g., 28 and 31), while bis(arylmethyl) derivatives (e.g., 10, 11, and 27), diethers (e.g., 49, 50, and 56), and diphenyl ethers (e.g., 35 and 36) were the least active. For the most biologically active compound 28, we observed as much as a 346% increase in serum HDL-cholesterol and a 71% reduction in serum triglycerides at the highest dose administered (100 mg/kg) after 2 weeks of treatment. For compound 31 we observed a 69% reduction in non-HDL-cholesterol, accompanied by a 131% increase in HDL-cholesterol and an 84% reduction in serum triglycerides under the same treatment conditions.


Asunto(s)
Ácidos Dicarboxílicos/síntesis química , Éteres/síntesis química , Hidrocarburos/síntesis química , Hipolipemiantes/síntesis química , Lípidos/biosíntesis , Animales , Células Cultivadas , HDL-Colesterol/sangre , Ácidos Dicarboxílicos/química , Ácidos Dicarboxílicos/farmacología , Éteres/química , Éteres/farmacología , Éteres Cíclicos/síntesis química , Éteres Cíclicos/química , Éteres Cíclicos/farmacología , Femenino , Hepatocitos/efectos de los fármacos , Hepatocitos/metabolismo , Hidrocarburos/química , Hidrocarburos/farmacología , Hipolipemiantes/química , Hipolipemiantes/farmacología , Lípidos/sangre , Masculino , Obesidad/sangre , Éteres Fenílicos/síntesis química , Éteres Fenílicos/química , Éteres Fenílicos/farmacología , Ratas , Ratas Sprague-Dawley , Ratas Zucker , Relación Estructura-Actividad , Triglicéridos/sangre
16.
J Med Chem ; 47(24): 6082-99, 2004 Nov 18.
Artículo en Inglés | MEDLINE | ID: mdl-15537362

RESUMEN

Keto-substituted hydrocarbons with 11-19 methylene and bis-terminal hydroxyl and carboxyl groups have been synthesized and evaluated in both in vivo and in vitro assays for their potential to favorably alter lipid disorders including metabolic syndrome. Compounds were assessed for their effects on the de novo incorporation of radiolabeled acetate into lipids in primary cultures of rat hepatocytes as well as for their effects on lipid and glycemic variables in obese female Zucker fatty rats [Crl:(ZUC)-faBR] following 1 and 2 weeks of oral administration. The most active compounds were found to be symmetrical with four to five methylene groups separating the central ketone functionality and the gem dimethyl or methyl/aryl substituents. Furthermore, biological activity was found to be greatest in both in vivo and in vitro assays for the tetramethyl-substituted keto diacids and diols (e.g., 10c, 10g, 14c), and the least active were shown to be the bis(arylmethyl) derivatives (e.g., 10e, 10f, 14f). Compound 14c dose-dependently elevated HDL-cholesterol, reduced triglycerides, and reduced NEFA, with a minimum effective dose of 30 mg/kg/day. Compound 1 g dose-dependently modified non-HDL-cholesterol, triglycerides, and nonesterified fatty acids, with a minimum effective dose of 10 mg/kg/day. At this dose, compound 10g elevated HDL-cholesterol levels 2-3 times higher than pretreatment levels, and a dose-dependent reduction of fasting insulin and glucose levels was observed.


Asunto(s)
Alcoholes/síntesis química , Ácidos Dicarboxílicos/síntesis química , Hidrocarburos/síntesis química , Hipolipemiantes/síntesis química , Cetoácidos/síntesis química , Cetonas/síntesis química , Lípidos/biosíntesis , Enfermedades Metabólicas/tratamiento farmacológico , Alcoholes/química , Alcoholes/farmacología , Animales , Células Cultivadas , HDL-Colesterol/biosíntesis , HDL-Colesterol/sangre , Diabetes Mellitus/tratamiento farmacológico , Diabetes Mellitus/metabolismo , Ácidos Dicarboxílicos/química , Ácidos Dicarboxílicos/farmacología , Relación Dosis-Respuesta a Droga , Femenino , Hepatocitos/efectos de los fármacos , Hepatocitos/metabolismo , Hidrocarburos/química , Hidrocarburos/farmacología , Hiperlipidemias/tratamiento farmacológico , Hiperlipidemias/metabolismo , Hipolipemiantes/química , Hipolipemiantes/farmacología , Cetoácidos/química , Cetoácidos/farmacología , Cetonas/química , Cetonas/farmacología , Masculino , Enfermedades Metabólicas/metabolismo , Ratas , Ratas Sprague-Dawley , Ratas Zucker
17.
PLoS One ; 9(4): e95807, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24769858

RESUMEN

High-density lipoprotein (HDL) is known to protect against atherosclerosis by promoting the reverse cholesterol transport. A new pathway for the regulation of HDL-cholesterol (HDL-c) removal involving F1-ATPase and P2Y13 receptor (P2Y13R) was described in vitro, and recently in mice. However, the physiological role of F1-ATPase/P2Y13R pathway in the modulation of vascular pathology i.e. in the development of atherosclerotic plaques is still unknown. We designed a specific novel agonist (CT1007900) of the P2Y13R that caused stimulation of bile acid secretion associated with an increased uptake of HDL-c in the liver after single dosing in mice. Repeated dose administration in mice, for 2 weeks, stimulated the apoA-I synthesis and formation of small HDL particles. Plasma samples from the agonist-treated mice had high efflux capacity for mobilization of cholesterol in vitro compared to placebo group. In apoE-/- mice this agonist induced a decrease of atherosclerotic plaques in aortas and carotids. The specificity of P2Y13R pathway in those mice was assessed using adenovirus encoding P2Y13R-shRNA. These results demonstrate that P2Y13R plays a pivotal role in the HDL metabolism and could also be a useful therapeutic agent to decrease atherosclerosis. In this study, the up-regulation of HDL-c metabolism via activation of the P2Y13R using agonists could promote reverse cholesterol transport and promote inhibition of atherosclerosis progression in mice.


Asunto(s)
Aterosclerosis/metabolismo , HDL-Colesterol/sangre , HDL-Colesterol/metabolismo , Morfolinas/farmacología , Agonistas del Receptor Purinérgico P2/farmacología , Pirimidinas/farmacología , Receptores Purinérgicos P2/fisiología , Animales , Apolipoproteínas E/genética , Aterosclerosis/tratamiento farmacológico , Arterias Carótidas/efectos de los fármacos , Arterias Carótidas/metabolismo , Arterias Carótidas/patología , Evaluación Preclínica de Medicamentos , Células Hep G2 , Humanos , Ratones Endogámicos C57BL , Ratones Noqueados , Placa Aterosclerótica/metabolismo , Agregación Plaquetaria/efectos de los fármacos
18.
Atherosclerosis ; 232(1): 110-8, 2014 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-24401224

RESUMEN

OBJECTIVE: CER-001 is a novel engineered HDL-mimetic comprised of recombinant human apoA-I and phospholipids that was designed to mimic the beneficial properties of nascent pre-ß HDL. In this study, we have evaluated the capacity of CER-001 to perform reverse lipid transport in single dose studies as well as to regress atherosclerosis in LDLr(-/-) mice after short-term multiple-dose infusions. APPROACH AND RESULTS: CER-001 induced cholesterol efflux from macrophages and exhibited anti-inflammatory response similar to natural HDL. Studies with HUVEC demonstrated CER-001 at a concentration of 500 µg/mL completely suppressed the secretion of cytokines IL-6, IL-8, GM-CSF and MCP-1. Following infusion of CER-001 (10mg/kg) in C57Bl/6J mice, we observed a transient increase in the mobilization of unesterified cholesterol in HDL particles containing recombinant human apoA-I. Finally we show that cholesterol elimination was stimulated in CER-001 treated animals as demonstrated by the increased cholesterol concentration in liver and feces. In a familial hypercholesterolemia mouse model (LDL-receptor deficient mice), the infusion of CER-001 caused 17% and 32% reductions in plaque size, 17% and 23% reductions in lipid content after 5 and 10 doses given every 2 days, respectively. Also, there was an 80% reduction in macrophage content in the plaque following 5 doses, and decreased VCAM-1 expression by 16% and 22% in the plaque following 5 and 10 intravenous doses of CER-001, respectively. CONCLUSION: These data demonstrate that CER-001 rapidly enhances reverse lipid transport in the mouse, reducing vascular inflammation and promoting regression of diet-induced atherosclerosis in LDLr(-/-) mice upon a short-term multiple dose treatment.


Asunto(s)
Apolipoproteína A-I/química , Aterosclerosis/tratamiento farmacológico , Biomimética , Lipoproteínas HDL/sangre , Fosfolípidos/química , Proteínas Recombinantes/farmacología , Animales , Apolipoproteína A-I/farmacología , Células CHO , Adhesión Celular , Colesterol/sangre , Colesterol/química , Cricetinae , Cricetulus , Relación Dosis-Respuesta a Droga , Heces , Células Endoteliales de la Vena Umbilical Humana , Humanos , Hiperlipoproteinemia Tipo II/tratamiento farmacológico , Inflamación , Lípidos/sangre , Lipoproteínas/química , Hígado/metabolismo , Macrófagos/citología , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Fosfolípidos/farmacología , Proteínas Recombinantes/química
19.
Mass Spectrom Rev ; 24(2): 223-31, 2005.
Artículo en Inglés | MEDLINE | ID: mdl-15389859

RESUMEN

Metabolomics, also known as Metabolic Profiling, is an emerging discipline under the umbrella concept of systems biology. The goal of metabolomics is to know and understand the concentrations and fluxes of endogenous metabolites within a living biological system under study. General tools are being developed for the rapid measurement of many metabolites in a single experiment, most of which are mass spectrometric methods. FT-ICR has unique advantages, as a mass spectrometric method, in this regard. Applications of FT-ICR to metabolomics analyses will be discussed and reviewed in the context of the single publication currently available.


Asunto(s)
Metabolismo Energético , Espectrometría de Masas/métodos , Espectroscopía Infrarroja por Transformada de Fourier , Biología de Sistemas/métodos
20.
Bioorg Med Chem ; 13(1): 223-36, 2005 Jan 03.
Artículo en Inglés | MEDLINE | ID: mdl-15582467

RESUMEN

A series of cycloalkyl-substituted oxo-alkanedicarboxylic acids have been prepared by the TosMIC methodology departing from haloalkyl-substituted cycloalkylcarboxylic esters. cyclopropyl derivatives showed IC(50) activity in the 0.3-1.0 microM range on the de novo incorporation of radiolabeled acetate into lipids in primary cultures of rat hepatocytes, and they showed lipid-regulating properties when tested in vivo in female obese Zucker fatty rats.


Asunto(s)
Ácidos Dicarboxílicos/farmacología , Lípidos/sangre , Lipoproteínas/sangre , Animales , Células Cultivadas , Ácidos Dicarboxílicos/química , Hepatocitos/efectos de los fármacos , Hepatocitos/metabolismo , Espectroscopía de Resonancia Magnética , Masculino , Espectrometría de Masas , Ratas , Ratas Sprague-Dawley
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA